JP4651191B2 - Ｍｃｐ−１タンパク質の生成を減らす際に活性がある薬剤組成物 - Google Patents

Ｍｃｐ−１タンパク質の生成を減らす際に活性がある薬剤組成物 Download PDF

Info

Publication number
JP4651191B2
JP4651191B2 JP2000503829A JP2000503829A JP4651191B2 JP 4651191 B2 JP4651191 B2 JP 4651191B2 JP 2000503829 A JP2000503829 A JP 2000503829A JP 2000503829 A JP2000503829 A JP 2000503829A JP 4651191 B2 JP4651191 B2 JP 4651191B2
Authority
JP
Japan
Prior art keywords
mcp
pharmaceutical composition
protein
composition according
reducing production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000503829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001510793A5 (enExample
JP2001510793A (ja
Inventor
グリールモッティ アンジェロ
マントヴァーニ アルベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of JP2001510793A publication Critical patent/JP2001510793A/ja
Publication of JP2001510793A5 publication Critical patent/JP2001510793A5/ja
Application granted granted Critical
Publication of JP4651191B2 publication Critical patent/JP4651191B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000503829A 1997-07-28 1998-07-22 Ｍｃｐ−１タンパク質の生成を減らす際に活性がある薬剤組成物 Expired - Fee Related JP4651191B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT97A01789 1997-07-28
IT97MI001789A IT1293795B1 (it) 1997-07-28 1997-07-28 Farmaco attivo nel ridurre la produzione di proteina mcp-1
PCT/EP1998/004924 WO1999004770A2 (en) 1997-07-28 1998-07-22 A pharmaceutical composition active in reducing production of mcp-1 protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009270715A Division JP5086322B2 (ja) 1997-07-28 2009-11-09 Ｍｃｐ−１プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物

Publications (3)

Publication Number Publication Date
JP2001510793A JP2001510793A (ja) 2001-08-07
JP2001510793A5 JP2001510793A5 (enExample) 2006-01-05
JP4651191B2 true JP4651191B2 (ja) 2011-03-16

Family

ID=11377642

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000503829A Expired - Fee Related JP4651191B2 (ja) 1997-07-28 1998-07-22 Ｍｃｐ−１タンパク質の生成を減らす際に活性がある薬剤組成物
JP2009270715A Expired - Fee Related JP5086322B2 (ja) 1997-07-28 2009-11-09 Ｍｃｐ−１プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009270715A Expired - Fee Related JP5086322B2 (ja) 1997-07-28 2009-11-09 Ｍｃｐ−１プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物

Country Status (15)

Country Link
US (1) US6534534B1 (enExample)
EP (1) EP1005332B1 (enExample)
JP (2) JP4651191B2 (enExample)
AR (1) AR016382A1 (enExample)
AT (1) ATE251902T1 (enExample)
AU (1) AU744492B2 (enExample)
CA (1) CA2300289C (enExample)
DE (1) DE69819012T2 (enExample)
DK (1) DK1005332T3 (enExample)
ES (1) ES2207858T3 (enExample)
IT (1) IT1293795B1 (enExample)
PT (1) PT1005332E (enExample)
SI (1) SI1005332T1 (enExample)
WO (1) WO1999004770A2 (enExample)
ZA (1) ZA986636B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010047609A (ja) * 1997-07-28 2010-03-04 Aziende Chimiche Riunite Angelini Francesco Acraf Spa Ｍｃｐ−１プロテインの軽減生産に活性な薬剤組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
LT2254869T (lt) 2008-03-07 2017-08-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška
CA2714436C (en) 2008-03-07 2017-06-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
JP5509102B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体およびそのｍｃｐ−１およびｃｘ３ｃｒ１の発現に基づく疾患の治療への使用
PL2462119T3 (pl) 2009-08-03 2014-10-31 Acraf Sposób wytwarzania 1-benzylo-3-hydroksymetylo-1H-indazolu i jego pochodnych oraz potrzebnych magnezowych związków pośrednich
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US9250253B2 (en) 2010-02-25 2016-02-02 Prairie Ventures, L.L.C. System and method for anatomical pathology sample handling, storage, and analysis
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
EP3142664B1 (en) * 2014-05-15 2019-12-04 Translatum Medicus Inc. Compositions and methods for treating and diagnosing ocular disorders
WO2016201426A1 (en) 2015-06-12 2016-12-15 Vettore, LLC Mct4 inhibitors for treating disease
IL279949B2 (en) 2016-12-12 2025-03-01 Vettore Llc Heterocyclic MCT4 inhibitors
US11753382B2 (en) 2019-06-25 2023-09-12 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
WO1994009128A1 (en) * 1992-10-22 1994-04-28 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
JPH08333262A (ja) * 1995-04-07 1996-12-17 Chugai Pharmaceut Co Ltd 免疫抑制剤
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19538402A1 (de) * 1995-10-14 1997-04-17 Boehringer Mannheim Gmbh Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel
JPH09165339A (ja) * 1995-10-27 1997-06-24 American Home Prod Corp ラパマイシンを付与したドナー脾細胞を用いる臓器移植の延長
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010047609A (ja) * 1997-07-28 2010-03-04 Aziende Chimiche Riunite Angelini Francesco Acraf Spa Ｍｃｐ−１プロテインの軽減生産に活性な薬剤組成物

Also Published As

Publication number Publication date
IT1293795B1 (it) 1999-03-10
CA2300289A1 (en) 1999-02-04
JP2010047609A (ja) 2010-03-04
HK1028561A1 (en) 2001-02-23
SI1005332T1 (en) 2004-02-29
US6534534B1 (en) 2003-03-18
DE69819012D1 (de) 2003-11-20
JP5086322B2 (ja) 2012-11-28
DK1005332T3 (da) 2004-02-09
AR016382A1 (es) 2001-07-04
WO1999004770A3 (en) 1999-04-15
ZA986636B (en) 1999-02-04
AU744492B2 (en) 2002-02-28
AU9160198A (en) 1999-02-16
JP2001510793A (ja) 2001-08-07
CA2300289C (en) 2007-11-20
ES2207858T3 (es) 2004-06-01
WO1999004770A2 (en) 1999-02-04
ITMI971789A1 (it) 1999-01-28
PT1005332E (pt) 2004-03-31
EP1005332A2 (en) 2000-06-07
DE69819012T2 (de) 2004-08-12
ATE251902T1 (de) 2003-11-15
EP1005332B1 (en) 2003-10-15

Similar Documents

Publication Publication Date Title
JP5086322B2 (ja) Ｍｃｐ−１プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物
DE69434490T2 (de) Zusammenstellungen zur Krebsbehandlung
JP2004531468A5 (enExample)
EP1369119B1 (en) Il-12 expression controlling agents
JP2609434B2 (ja) 抗菌性インターフェロン誘発性医薬品
US6890906B2 (en) Method for controlling angiogenesis in animals
RU2152215C1 (ru) Применение ропивакаина при изготовлении фармацевтического препарата с анальгезирующим действием с минимальной моторной блокадой
US6191158B1 (en) Pharmaceutical composition active in reducing production of MCP-1 protein
JP2002515035A (ja) アミノステロール化合物の治療学的使用
JP3587851B2 (ja) Ｔｎｆ誘発病状の治療におけるベンジダミンの使用
HK1028561B (en) Pharmaceutical composition for reducing production of mcp-1 protein
JPH03193730A (ja) 治療剤
MXPA00001003A (en) A pharmaceutical composition active in reducing production of mcp-1 protein
EP1203585A1 (en) Anti-ischemic agent
JPS58501949A (ja) 患者の血清中の低密度リポタンパク質レベルを低減させる方法
CZ2000292A3 (cs) Farmaceutický prostředek aktivní při snižování produkce proteinu MCP-1
CN118490681A (zh) 瑞香素在制备治疗淋巴回流障碍的药物中的应用
RU2141828C1 (ru) Средство, пролонгирующее эффективность чесночного порошка
JPH11106337A (ja) 乾癬の処置剤
CN112358477A (zh) 一种用于治疗胆囊炎的药物及其制备方法
CN110833547A (zh) 吡唑并嘧啶衍生物在治疗类风湿关节炎的用途
Mouihate et al. FINAL ACCEPTED VERSION R-00250-2006. R1
KR20040083901A (ko) 카텝신 비 저해물질을 유효성분으로 함유하는관절염치료제 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090508

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100204

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100730

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101116

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101214

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees